About OnQuality
OnQuality is a company based in Shanghai (China) founded in 2018 by Shiyi Zhang. OnQuality has raised $20 million across 1 funding round from investors including Shiyu Capital, Matrix Partners China and BioTrack Capital. OnQuality offers products and services including Cancer Supportive Care Treatments. OnQuality operates in a competitive market with competitors including Philogen, Aura Biosciences, SkinJect, Therakos and Pokeacell, among others.
- Headquarter Shanghai, China
- Founders Shiyi Zhang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Onquality Pharmaceuticals Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20 M (USD)
in 1 rounds
-
Latest Funding Round
$20 M (USD), Series A
Mar 31, 2021
-
Investors
Shiyu Capital
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OnQuality
OnQuality offers a comprehensive portfolio of products and services, including Cancer Supportive Care Treatments.
Treatments to alleviate side effects of cancer drugs for better patient outcomes.
People of OnQuality
Unlock access to complete
Leadership Team
1 people
Software Development Team
1 people
Co Team
1 people
Founder Team
1 people
Project Team
1 people
Unlock access to complete
Funding Insights of OnQuality
OnQuality has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Series A round of $20 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OnQuality
OnQuality has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Shiyu Capital, Matrix Partners China and BioTrack Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Shiyu Capital is engaged in equity investment and asset allocation.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by this venture capital firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for OnQuality
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OnQuality
Investment portfolio details for OnQuality
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OnQuality
Detailed financials for OnQuality
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Onquality Comparisons
Peer comparison for OnQuality
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OnQuality
OnQuality operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Philogen, Aura Biosciences, SkinJect, Therakos and Pokeacell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for angiogenesis-related cancers and disorders.
|
|
| Locked | Locked | Locked |
Therapies are developed to target and destroy cancer cells selectively.
|
|
| Locked | Locked | Locked |
Dissolvable microneedle patches for non-melanoma skin cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therakos is focused on photopheresis systems for CTCL treatment.
|
|
| Locked | Locked | Locked |
T cell therapies for cancer treatment are developed by Pokeacell.
|
Detailed competitors of OnQuality
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Onquality
Complete news archive for OnQuality
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OnQuality
OnQuality was founded in 2018 and raised its 1st funding round 3 years after it was founded.
OnQuality is headquartered in Shanghai, China.
Michael McCullar is the current CEO of OnQuality.
OnQuality is a funded company, having raised a total of $20M across 1 funding round to date.
OnQuality was founded in 2018 in Shanghai, China, within the biotechnology sector. Focus is placed on developing therapeutics targeting skin cancers and associated adverse reactions. The product pipeline includes OQL011 for VEGFR inhibitor-induced hand-foot skin reactions, OQL023 for skin rashes, and OQL033 for chemotherapy-induced hand-foot syndrome. Operations center on advancing these treatments for dermatological conditions in oncology.
OnQuality's top competitors include Philogen, Aura Biosciences and Therakos.
OnQuality offers Cancer Supportive Care Treatments.
OnQuality has 6 investors. Key investors include Shiyu Capital, Matrix Partners China, BioTrack Capital, Sinovation Ventures, and Frees Fund.